Executive Summary
Azoth Analytics has released a research report titled "Global Irritable Bowel Disease Market (2024 Edition)" which provides a complete analysis of the Global Irritable Bowel Disease industry in terms of market segmentation By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By Route of Administration (Injectable and Oral ), By Indication (Crohn's Disease and Ulcerative Colitis) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022. The market was valued at USD 21.45 Billion in 2022 which is expected to reach USD 27.16 Billion in 2029. The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
The global IBD market has been steadily growing, driven by factors such as increasing incidence and prevalence of IBD worldwide. According to recent studies, the prevalence of IBD is rising globally, affecting millions of individuals across all age groups. This increasing prevalence has led to a surge in demand for effective treatments and diagnostics, thereby fueling market growth.
The landscape of IBD treatment has undergone a paradigm shift with continuous therapeutic innovations. Biologic agents targeting specific inflammatory pathways have emerged as effective treatments for moderate to severe IBD, offering improved disease management and symptom control.
Moreover, personalized medicine approaches, driven by advancements in pharmacogenomics and precision medicine, are increasingly being explored to tailor treatments according to individual patient profiles. Furthermore, research into microbiome modulation and gut-targeted therapies holds promise for novel treatment modalities in the future.
The global market for Irritable Bowel Disease is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.
Scope of the Report:
• The report analyses the Irritable Bowel Disease Market by Value (USD Billion).
• The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
• The report presents the analysis of Irritable Bowel Disease Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
• The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
• The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Classes, by Route of Administration & by Indication.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Pfizer, Novartis AG, Eli Lilly and Company, AbbVie Inc., GSK plc., UCB S.A, Takeda Pharmaceuticals, Bristol-Myers Squibb Co. and Celltrion.
Table of Content
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Shift towards Small Molecule Therapies
2.2 Diversification of Therapeutic Targets
3. Global Irritable bowel disease Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Irritable bowel disease Market
3.2 Share of Leading TNF inhibitor drugs in market for Ulcerative colitis
3.3 Prevalence of Irritable Bowel Disease, 2019
3.4 Incidence of Irritable Bowel Disease, 2019
3.5 Select emergent therapies in clinical development for UC
3.6 Global Irritable bowel disease Market : Dashboard
3.7 Global Irritable bowel disease Market: Market Value Assessment, 2019-2029 (USD Billion)
3.8 Global Irritable bowel disease Market: Market Value Assessment
3.9 Assessment Degree of Impact of COVID-19 on Global Irritable bowel disease Market
3.10 Global Irritable bowel disease Market Segmentation: By Drug Class
3.10.1 Global Irritable bowel disease Market, By Drug Class Type Overview
3.10.2 Global Irritable bowel disease Market Attractiveness Index, By Drug Class
3.10. Global Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.4 Global Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.5 Global Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
3.10.6 Global Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
3.11 Global Irritable bowel disease Market Segmentation: By Route of Administration
3.11.1 Global Irritable bowel disease Market, By Route of Administration Overview
3.11.2 Global Irritable bowel disease Market Attractiveness Index, By Route of Administration
3.11.3 Global Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
3.11.4 Global Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
3.12 Global Irritable bowel disease Market Segmentation: By Indication
3.12.1 Global Irritable bowel disease Market, By Indication Overview
3.12.2 Global Irritable bowel disease Market Attractiveness Index, By Indication
3.12.3 Global Irritable bowel disease Market Size, By Crohn's DiseaseBy Value, 2019H-2029F (USD Billion & CAGR)
3.12.4 Global Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
4. Global Irritable bowel disease Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
5. Americas Irritable bowel disease Market: Historic and Forecast
5.1 Americas Irritable bowel disease Market: Snapshot
5.2 Americas Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.3 Americas Irritable bowel disease Market: Key Factors
5.4 Americas Irritable bowel disease Market: Segment Analysis
5.5 Americas Irritable bowel disease Market Segmentation: By Drug Class
5.5.1 Americas Irritable bowel disease Market, By Drug Class Overview
5.5.2 Americas Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.3 Americas Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.4 Americas Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
5.5.5 Americas Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
5.6 Americas Irritable bowel disease Market Segmentation: By Route of Administration
5.6.1 Americas Irritable bowel disease Market, By Route of Administration Overview
5.6.2 Americas Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
5.6.3 Americas Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
5.7 Americas Irritable bowel disease Market Segmentation: By Indication
5.7.1 Americas Irritable bowel disease Market, By Indication Overview
5.7.2 Americas Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
5.7.3 Americas Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
5.8 Americas Irritable bowel disease Market Segmentation : By Country
5.8.1 Americas Irritable bowel disease Market, by Country Overview
5.8.2 United States Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.2.1 United States Irritable bowel disease Market, By Drug Class
5.8.2.2 United States Irritable bowel disease Market, By Route of Administration
5.8.2.3 United States Irritable bowel disease Market, By Indication
5.8.3 Canada Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.3.1 Canada Irritable bowel disease Market, By Drug Class
5.8.3.2 Canada Irritable bowel disease Market, By Route of Administration
5.8.3.3 Canada Irritable bowel disease Market, By Indication
5.8.4 Rest of Americas Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.8.4.1 Rest of Americas Irritable bowel disease Market, By Drug Class
5.8.4.2 Rest of Americas Irritable bowel disease Market, By Route of Administration
5.8.4.3 Rest of Americas Irritable bowel disease Market, By Indication
6. Europe Irritable bowel disease Market: Historic and Forecast
6.1 Europe Irritable bowel disease Market: Snapshot
6.2 Europe Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.3 Europe Irritable bowel disease Market: Key Factors
6.4 Europe Irritable bowel disease Market: Segment Analysis
6.5 Europe Irritable bowel disease Market Segmentation: By Drug Class
6.5.1 Europe Irritable bowel disease Market, By Drug Class Overview
6.5.2 Europe Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.3 Europe Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.4 Europe Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
6.5.5 Europe Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
6.6 Europe Irritable bowel disease Market Segmentation: By Route of Administration
6.6.1 Europe Irritable bowel disease Market, By Route of Administration Overview
6.6.2 Europe Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
6.6.3 Europe Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
6.7 Europe Irritable bowel disease Market Segmentation: By Indication
6.7.1 Europe Irritable bowel disease Market, By Indication Overview
6.7.2 Europe Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
6.7.3 Europe Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
6.8 Europe Irritable bowel disease Market Segmentation : By Country
6.8.1 Europe Irritable bowel disease Market, by Country Overview
6.8.2 United Kingdom Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.2.1 United Kingdom Irritable bowel disease Market, By Drug Class
6.8.2.2 United Kingdom Irritable bowel disease Market, By Route of Administration
6.8.2.3 United Kingdom Irritable bowel disease Market, By Indication
6.8.3 Germany Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.3.1 Germany Irritable bowel disease Market, By Drug Class
6.8.3.2 Germany Irritable bowel disease Market, By Route of Administration
6.8.3.3 Germany Irritable bowel disease Market, By Indication
6.8.4 France Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.4.1 France Irritable bowel disease Market, By Drug Class
6.8.4.2 France Irritable bowel disease Market, By Route of Administration
6.8.4.3 France Irritable bowel disease Market, By Indication
6.8.5 Italy Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.5.1 Italy Irritable bowel disease Market, By Drug Class
6.8.5.2 Italy Irritable bowel disease Market, By Route of Administration
6.8.5.3 Italy Irritable bowel disease Market, By Indication
6.8.6 Spain Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.6.1 Spain Irritable bowel disease Market, By Drug Class
6.8.6.2 Spain Irritable bowel disease Market, By Route of Administration
6.8.6.3 Spain Irritable bowel disease Market, By Indication
6.8.7 Rest of Europe Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.8.7.1 Rest of Europe Irritable bowel disease Market, By Drug Class
6.8.7.2 Rest of Europe Irritable bowel disease Market, By Route of Administration
6.8.7.3 Rest of Europe Irritable bowel disease Market, By Indication
7. Asia-Pacific Irritable bowel disease Market: Historic and Forecast
7.1 Asia-Pacific Irritable bowel disease Market: Snapshot
7.2 Asia-Pacific Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.3 Asia-Pacific Irritable bowel disease Market: Key Factors
7.4 Asia-Pacific Irritable bowel disease Market: Segment Analysis
7.5 Asia-Pacific Irritable bowel disease Market Segmentation: By Drug Class
7.5.1 Asia-Pacific Irritable bowel disease Market, By Drug Class Overview
7.5.2 Asia-Pacific Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.3 Asia-Pacific Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.4 Asia-Pacific Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
7.5.5 Asia-Pacific Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
7.6 Asia-Pacific Irritable bowel disease Market Segmentation: By Route of Administration
7.6.1 Asia-Pacific Irritable bowel disease Market, By Route of Administration Overview
7.6.2 Asia-Pacific Irritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
7.6.3 Asia-Pacific Irritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
7.7 Asia-Pacific Irritable bowel disease Market Segmentation : By Indication
7.7.1 Asia-Pacific Irritable bowel disease Market, By Indication Overview
7.7.2 Asia-Pacific Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
7.7.3 Asia-Pacific Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
7.8 Asia-Pacific Irritable bowel disease Market Segmentation : By Country
7.8.1 Asia Pacific Irritable bowel disease Market, by Country Overview
7.8.2 China Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.2.1 China Irritable bowel disease Market, By Drug Class
7.8.2.2 China Irritable bowel disease Market, By Route of Administration
7.8.2.3 China Irritable bowel disease Market, By Indication
7.8.3 Japan Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.3.1 Japan Irritable bowel disease Market, By Drug Class
7.8.3.2 Japan Irritable bowel disease Market, By Route of Administration
7.8.3.3 Japan Irritable bowel disease Market, By Indication
7.8.4 India Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.4.1 India Irritable bowel disease Market, By Drug Class
7.8.4.2 India Irritable bowel disease Market, By Route of Administration
7.8.4.3 India Irritable bowel disease Market, By Indication
7.8.5 Rest of Asia Pacific Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.8.5.1 Rest of Asia Pacific Irritable bowel disease Market, By Drug Class
7.8.5.2 Rest of Asia Pacific Irritable bowel disease Market, By Route of Administration
7.8.5.3 Rest of Asia Pacific Irritable bowel disease Market, By Indication
8. Middle-East & Africa Irritable bowel disease Market: Historic and Forecast
8.1 Middle-East & Africa Irritable bowel disease Market: Snapshot
8.2 Middle-East & Africa Irritable bowel disease Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
8.3 Middle-East & Africa Irritable bowel disease Market: Key Factors
8.4 Middle-East & Africa Irritable bowel disease Market: Segment Analysis
8.5 Middle-East & Africa Irritable bowel disease Market Segmentation: By Drug Class
8.5.1 Middle-East & Africa Irritable bowel disease Market, By Drug Class Overview
8.5.2 Middle-East & Africa Irritable bowel disease Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.3 Middle-East & Africa Irritable bowel disease Market Size, By JAK inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.4 Middle-East & Africa Irritable bowel disease Market Size, By TNF inhibitors, By Value, 2019H-2029F (USD Billion & CAGR)
8.5.5 Middle-East & Africa Irritable bowel disease Market Size, By Other Drug Classes, By Value, 2019H-2029F (USD Billion & CAGR)
8.6 Middle-East & AfricaIrritable bowel disease Market Segmentation: By Route of Administration
8.6.1 Middle-East & AfricaIrritable bowel disease Market, By Route of Administration Overview
8.6.2 Middle-East & AfricaIrritable bowel disease Market Size, By Injectable, By Value, 2019H-2029F (USD Billion & CAGR)
8.6.3 Middle-East & AfricaIrritable bowel disease Market Size, By Oral, By Value, 2019H-2029F (USD Billion & CAGR)
8.7 Middle-East & Africa Irritable bowel disease Market Segmentation: By Indication
8.7.1 Middle-East & Africa Irritable bowel disease Market, By Indication: Overview
8.7.2 Middle-East & Africa Irritable bowel disease Market Size, By Crohn's Disease, By Value, 2019H-2029F (USD Billion & CAGR)
8.7.3 Middle-East & Africa Irritable bowel disease Market Size, By Ulcerative Colitis, By Value, 2019H-2029F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Global Irritable bowel disease Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter's Five Forces Model
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Irritable bowel disease Market
11.4 Company Profiles
11.4.1 Johnson & Johnson
11.4.2 Pfizer
11.4.3 Novartis AG
11.4.4 Eli Lilly and Company
11.4.5 AbbVie Inc.
11.4.6 GSK Plc.
11.4.7 UCB S.A
11.4.8 Takeda Pharmaceuticals
11.4.9 Bristol-Myers Squibb Co.
11.4.10 Celltrion
12. About Us & Disclaimer
The Chronic Kidney Disease Management Technology Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive l...
The Industrial Disease Prevention Systems Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscap...
Market Overview
The Asia Pacific Neurofibromatosis Treatment Market is anticipated to witness substantial growth from 2024 to 2034, driven by increasing awareness and diagnosis of neurofibromatosis (NF), advancements in treatment options, and a growing patient population. The market is ...
Market Overview
The Europe Neurofibromatosis Treatment Market is projected to experience substantial growth from 2024 to 2034, driven by advancements in medical treatments, increasing prevalence of neurofibromatosis disorders, and rising awareness about these conditions. The market is e...
Market Overview
The North America Neurofibromatosis Treatment Market is poised for substantial growth from 2024 to 2034, driven by advancements in medical research, increased awareness of neurofibromatosis (NF), and the development of novel therapies. The market size is anticipated to r...
Market Overview
The Global Neurofibromatosis Treatment Market is projected to witness significant growth from 2024 to 2034, driven by advancements in medical research, increasing awareness about neurofibromatosis, and the development of novel therapies. Valued at USD XX.XX billion in 20...
The Chronic Heart Disease Management Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, ma...
The Autoimmune Disease Therapies Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufa...
The Digital Platform for Chronic Kidney Disease Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive la...
The Kidney Disease Digital Platform Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, man...